16.19.20.45 PRESCRIPTION FILL AND REFILL REQUIREMENTS

16.19.20.45 PRESCRIPTION FILL AND REFILL REQUIREMENTS:

A. Prescriptions for any controlled substance shall not be filled more than six months after the date of

issue.

(1) Controlled substance prescriptions dispensed directly to a patient shall not be refilled

before seventy-five percent of the prescription days’ supply has passed, unless the practitioner authorizes the early

refill, which must be documented by the pharmacist.

(2) Controlled substance prescriptions delivered to a patient indirectly (as mail order) to a

patient shall not be refilled before sixty-six percent of a 90 day supply has passed or fifty percent of a 30 day supply

has passed, unless the practitioner authorizes the early refill, which must be documented by the pharmacist.

B. Prescriptions for Schedule III, IV, or V controlled substances shall not be filled or refilled more

than six months after the date of issue or be filled refilled more than five times unless renewed by the practitioner

and a new prescription is placed in the pharmacy files.

[16.19.20.45 NMAC - Rp 16 NMAC 19.20.20(4), 07-15-02; A, 08-31-12; A, 10-19-16]

16.19.20.46 PRESCRIPTION - PARTIALLY REFILLED:

A. A prescription for a controlled substance in Schedule II may be partially filled if the total quantity

dispensed in all partial fillings does not exceed the total quantity prescribed. Remaining portions shall be filled not

later than 30 days after the date on which the prescription is written.

B. A Schedule II prescription may be partially filled if the amount is recorded on the prescription.

The remaining portion may be filled within 72 hours of the partial filling for prescriptions initially filled later than

30 days after the date on which the prescription is written. Pharmacist must notify the prescribing physician if

remaining portion cannot be filled within a 72 hour period.

BC. Partial filling of a prescription for Schedule III or IV shall be recorded in the same manner as a

refill, providing the total quantity of partial filling does not exceed the total quantity prescribed and no dispensing

occurs after six months from date of prescription.

CD. A prescription for a Schedule II controlled substance written for a patient in a long term care

facility (LTCF) or for a patient with a medical diagnosis documenting a terminal illness may be filled in partial

quantities, to include individual dosage units.

(1) If there is any question whether a patient may be classified as having a terminal illness,

the pharmacist shall contact the practitioner prior to partially filling the prescription. Both the pharmacist and the

prescribing practitioner have a corresponding responsibility to assure that the controlled substance is for a terminally

ill patient. The pharmacist shall record on the prescription whether the patient is “terminally ill” or an “LTCF

patient”.

(2) A prescription that is partially filled and does not contain the notation “terminally ill” or

LTCF patient” shall be deemed to have been filled in violation of this regulation. For each partial filling, the

dispensing pharmacist shall record on the back of the prescription (or on appropriate record, uniformly maintained,

and readily retrievable) the date of the partial filling, quantity dispensed, remaining quantity authorized to be

dispensed and the identification of the dispensing pharmacist.

(3) The total quantity of Schedule II controlled substances dispensed in all partial fillings

shall not exceed the total quantity prescribed. Schedule II prescriptions, for patients in a LTCF or patients with a

medical diagnosis documenting a terminal illness, shall be valid for a period not to exceed 60 days from the issue

date unless sooner terminated by the discontinuance of medication.

[16.19.20.46 NMAC - Rp 16 NMAC 19.20.20(5), 07-15-02; A, 03-29-17]

16.19.20.65 SCHEDULE I:

A. Section 30-31-6 NMSA 1978, Schedule I shall consist of the following drugs and other

substances, by whatever name, common or usual name, chemical name or brand name designated, listed in this

section; OPIATES NARCOTIC DRUGS, unless specifically exempt or unless listed in another schedule, any of

the following opiates narcotic drugs, including its isomers, esters, ethers, salts and salts of isomers, esters, and

ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical

designation.

(1) Acetylmethadol

(2) Allylprodine

(3) Alphacetylmethadol

(4) Alphameprodine

(5) Alphamethadol

(6) Alpha-methyl fentanyl

(7) Benzethidine

(8) Betacetylmethadol

(9) Betameprodine

(10) Betamethadol

(11) Betaprodine

(12) Clonitazene

(13) Desmethyltramadol

(14) Dextromoramide

(15) Diampromide

(16) Diethylthiambutene

(17) Dimethylthiambutene

(18) Difenoxin

(19) Dimenoxadol

(20) Dimepheptanol

(21) Dimethylthiambutene

(22) Dioxaphetyl Butyrate

(23) Dipipanone

(24) Ethylmethylthiambutene

(25) Etonitazene

(26) Etoxeridine

(27) Furethidine

(28) Hydroxypethidine

(29) Ketobemidone

(30) Levomoramide

(31) Levophenacylmorphan

(32) Morpheridine

(33) Noracymethadol

(34) Norlevorphanol

(35) Normethadone

(36) Norpipanone

(37) Phenadoxone

(38) Phenampromide

(39) Phenomorphan

(40) Phenoperidine

(41) Piritramide

(42) Proheptazine

(43) Properidine

(44) Propiram

(45) Racemoramide

(46) Tilidine

(47) Trimeperidine

(24)(48) Beta-Hydroxy-3-Methylfentanyl

(25)(49) 3-Methylthiofentanyl

(26)(50) Acetyl-Alpha-Methyl fentanyl

(27)(51) Alpha-Methylthiofentanyl

(28)(52) Beta-hydroxfentanyl

(29)(53) Para-Fluoro fentanyl

(30)(54) Thiofentanyl

(32)(55) Acetyl fentanyl

(33)(56) Butyryl fentanyl

(34)(57) Betahydroxythiofentanyl

(35)(58) Furanyl fentanyl

(36)(59) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)

(37)(60) U47700 (trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide)

(38)(61) MT-45 (1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide)

(39)(62) W-15 (4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide)

(40)(63) W-18 (1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide)

(41)(64) U-50488 (2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-

ylcyclohexyl]acetamide)

(42)(65) U50488H ((-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)cyclo-

hexyl]benzeneacetamide)

(66) Fentanyl mimetic substances that are any substances derived from fentanyl by any

substitution in the phenethyl group, any substitution in the piperidine ring, any substitution in the aniline ring, any

replacement of the phenyl portion of the phenethyl group, any replacement of the N-propionyl group or any

combination of the above.

(1)(67) 3-methylfentanyl(N-3-methyl-1-(2-phenyl-ethyl)-4-Piperidyl)-N-phenylpropanamide, its

optical and geometric isomers, salts and salts of isomers;

(3)(68) 1-methyl-4-phenyl-4-proprionoxypiperidine (MPPP), its optical isomers, salts, and salts

of isomers;

(69) Acrylfentanyl

(70) 4F-butyrfentanyl

(71) 4-methoxybutyrfentanyl

(72) Fluorobutyrfentanyl

(73) Fluorofentanyl

(74) Para Fluoro Isobutyryl Fentanyl (FIBF)

(75) Cyclopropyl fentanyl

(76) Thiofuranyl fentanyl (Thiophene fentanyl)

(77) U-48800

(78) U-49900

B. OPIUM DERIVATIVES: Unless specifically exempt or unless listed in another schedule, any of

the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers

and salts of isomers is possible within the specific chemical designation.

(1) Acetorphine

(2) Acetyl dihydrocodeine

(3) Benzyl morphine

(4) Codeine methylbromide

(5) Codeine-N-Oxide

(6) Cyprenorphine

(7) Desomorphine

(8) Dehydro morphine

(9) Etorphine

(10) Heroin

(11) Hydromorphinol

(12) Methyldesorphine

(13) Methyldihydromorphine

(14) Morphine methylbromide

(15) Morphine methylsulfonate

(16) Morphine-N-Oxide

(17) Myrophine

(18) Nicocodeine

(19) Nicomorphine

(20) Normorphine

(21) Pholcodine

(22) Thebacon

(23) Drotebanol

(24) Beta-Hydroxy-3-Methylfentanyl

(25) 3-Methylthiofentanyl

(26) Acetyl-Alpha-Methyl fentanyl

(27) Alpha-Methylthiofentanyl

(28) Beta-hydroxfentanyl

(29) Para-Fluoro fentanyl

(30) Thiofentanyl

(31) 6-acetylmorphine (6AM)

(32) Acetyl fentanyl

(33) Butyryl fentanyl

(34) Betahydroxythiofentanyl

(35) Furanyl fentanyl

(36) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)

(37) U47700 (trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide)

(38) MT-45 (1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide)

(39) W-15 (4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide)

(40) W-18 (1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide)

(41) U-50488 (2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-

ylcyclohexyl]acetamide)

(42) U50488H ((-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)cyclo-

hexyl]benzeneacetamide)

(24) 6-acetylmorphine (6AM)

E.C. STIMULANTS: Unless specifically exempted or unless listed in another schedule, any

material, compound, mixture or preparation which contains any quantity of the following substances having a

stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers.

(1) fenethylline;

(2) N-ethylamphetamine;

(3) cis-4-methylaminorex;

(4) N, N-dimethylamphetamine;

(5) N-benzylpiperazine (BZP, 1-benzylpiperazine);

(6) 2,3-dichlorophenylpiperazine (DCPP);

(7) dibenzylpiperazine (DBZP);

(8) methylbenzylpiperazine (MBZP);

(9) meta-chlorophenylpiperazine (mCPP);

(10) methylenedioxybenzylpiperazine (MDBZP);

(11) para-methoxyphenylpiperazine (meOPP);

(12) para-chlorophenylpiperazine (pCPP);

(13) para-fluorophenylpiperazine (pFPP);

(14) 2-diphenylmethylpiperidine, (2-DPMP, desoxypipradrol);

(15) diphenyl-2-pyrrolidinemethanol (D2PM, diphenylprolinol);

(16) methylnaphthidate (HDMP-28);

(17) 3α-carbomethoxy-4β-(4-chlorophenyl)-N-methylpiperidine (Nocaine, (+)-CPCA);

(18) butyltolylquinuclidine (2-Butyl-3-(p-tolyl)quinuclidine, BTQ);

D. DEPRESSANTS: Unless specifically exempt or unless listed in another schedule, any material,

compound, mixture or preparation which contains any quantity of the following substances having a depressant

effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such

salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) mecloqualone;

(2) methaqualone;

(3) benzodiazepines;

(a) bromazepam;

(b) camazepam;

(d) delorazepam;

(e) ethylloflazepate;

(f) fludiazepam;

(g) flunitrazepam;

(h) haloxazolam;

(i) ketazolam;

(j) loprazolam;

(k) lormetazepam;

(l) medazepam;

(m) nimetazepam;

(n) nitrazepam;

(o) nordiazepam;

(p) oxazolam;

(q) pinazepam;

(r) tetrazepam;

(s) flubromazepan

(t) diclazepam

(4) gamma hydroxybutyric acid and any chemical compound that is metabolically converted

to GHB;

(5) gamma butyrolactone and any chemical compound that is metabolically converted to

GHB;

(6) 1-4 butane diol and any chemical compound that is metabolically converted to GHB;

(7) γ-hydroxyvaleric acid (GHV, 4-methyl-GHB);

(8) γ-valerolactone (GVL);

(9) methylmethaqualone (MMQ);

(10) mebroqualone (MBQ);

C.E. HALLUCINOGENIC SUBSTANCES: Unless specifically exempt or unless listed in another schedule,

any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic

substances, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts,

isomers and salts of isomers is possible within the specific chemical designation (for purpose of this sub-section

only, the term “isomers” includes the optical position, optical, positional and geometric isomers).

(1) 3,4 -methylenedioxy amphetamine;

(2) 5 - methoxy - 3,4-methylenedioxy amphetamine;

(3) 3,4,5 -trimethoxy amphetamine;

(4) Bufotenine;

(5) Diethyltryptamine; DET;

(6) Dimethyltryptamine; DMT;

(7) 4-methyl-2,5-dimethoxy-amphetamine; DOM or STP;

(8) Lysergic acid amide;

(9) Lysergic acid diethylamide;

(10) Marijuana;

(11) Mescaline;

(12) Peyote;

(13) N-ethyl-3-piperidyl benzilate;

(14) N-methyl-3-piperidyl benzilate;

(15) Psilocybin;

(16) Psilocyn;

(17) Tetrahydrocannabinols;

(18) Parahexyl (synthetic analog of delta-9-tetrahydrocannabinol (THC) an active ingredient

of cannabis);

(19) Hashish;

(20) 2, 5 -dimethoxyamphetamine; 2, 5-DMA;

(21) 4-bromo-2, 5-dimethoxy-amphetamine; 2, 5-DMA;

(22) 4-methoxyamphetamine; PMA;

(23) Ethylamine N-ethyl-1-phenylcyclohexylamine (PCE);

(24) Pyrrolidine 1-(1-phenylcyclohexyl)-pyrrolidine (PCPy), (PHP) analog of the drug

phencyclidine;

(25) Thiophene (analog of phencyclidine) TCP or TPCP;

(26) Alpha-ethyltryptamine;

(27) 2, 5-dimethoxy-4-ethylamphet-amine;

(28) Ibogaine;

(29) 2,.5 dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7);

(30) Alpha-methyltryptamine (AMT);

(31) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);

(32) 2-(4-bromo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);

(33) 2-(4-chloro-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);

(34) 2-(4-iodo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);

(35) Synthetic cannabinoids: Unless specifically exempted or unless listed in another

schedule, any material, compound, mixture of or preparation which contains any quantity of the following synthetic

cannabinoids which demonstrates binding activity to the cannabinoid receptor or analogs or homologs with binding

activity:

(a) CP 55,244 ((hydroxymethyl)-4-[2-hydroxy-4-(2-methyloctan-2-yl)phenyl]

1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol);

(b) CP 55,940 (5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-

yl)phenol);

(d) JWH-122 (1-pentyl-3-(4-methyl-1-naphthoyl)indole);

(e) JWH-133 3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H

dibenzo[b,d]pyran;

(f) JWH 203 1-pentyl-3-(2-chlorophenylacetyl)indole);

(g) JWH 210 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone;

(h) AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole);

(i) AM-1221 (1-(N-methylpiperdin-2-yl)methyl-2-methyl-3-(1-naphthoyl)-6-

nitroindole;

(j) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole);

(k) RCS-4 or SR-19 (1-pentyl-3-[(4-methoxy)-benzoyl]indole);

(l) RCS-8 or SR-18 (1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole);

(m) JWH-210 (1-pentyl-3-(4-ethylnaphthoyl)indole);

(n) WIN-49,098 (Pravadoline) (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-

ylethyl)indol-3-yl]methanone;

(o) WIN-55,212-2 (2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-1,4-

benzooxazin6- yl)-1-naphthalenylmethanone);

(p) any of the following synthetic cannabinoids, their salts, isomers, and salts of

isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible

within the specific chemical designation;

(i) naphthoylindoles: any compound containing a 3-(1- naphthoyl) indole

structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,

cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further

substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent

including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210,

JWH-398 and AM-2201;

(ii) naphthylmethylindoles: any compound containing a1Hindol- 3-yl-(1-

naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or

not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any

extent including, but not limited to, JWH-175, JWH-184, and JWH-199;

(iii) naphthoylpyrroles: any compound containing a 3-(1- naphthoyl)

pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or

not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any

extent including, but not limited to, JWH-307;

(iv) naphthylmethylindenes: any compound containing a

naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or

not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any

extent including, but not limited to, JWH-176;

(v) phenylacetylindoles: any compound containing a 3- phenylacetylindole

structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,

cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further

substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including,

but not limited to, JWH-203, JWH-250, JWH-251, and RCS-8;

(vi) cyclohexylphenols: any compound containing a 2-(3-

hydroxycyclohexyl) phenol structure with substitution at the 5- position of the phenolic ring by an alkyl, haloalkyl,

alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group,

whether or not substituted in the cyclohexyl ring to any extent including, but not limited to, Cannabicyclohexanol

(CP 47,497 C8 homologue), CP 47,497 and CP 55,490;

(vii) benzoylindoles: any compound containing a 3-(benzoyl) [ 5 ] OTS-

3833.4 indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4- morpholinyl) ethyl group, whether or

not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent

including, but not limited to, AM-694, Pravadoline (WIN 48,098), RCS-4, and AM-1241;

(q) UR-144 1-(pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;

(r) XLR11 1-(5-fluoro-pentyl)-1H-indol-3-yl(2,2,3,3-

tetramethylcyclopropyl)methanone;

(s) AKB48 N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide;

(t) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22, QUPIC);

(u) Quinolin-8-yl 1-(5-fluropentyl-1H-indole-3-carboxylate (5-fluoro-PB22; 5F-

PB22);

(v) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-flurobenzyl)-1H-indazole-3-

carboxamide (AB-FUBINACA);

(w) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-

carboxamine (ADB-PINACA);

(x) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-

carboxamide (AB-CHMINACA);

(y) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide

(AB-PINACA);

(z) [1-(5-fluropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201);

(aa) FDU-PB-22 IUPAC: 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3 carboxylate;

(bb) 5-fluoro ABICA IUPAC: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-

fluoropentyl)-1H-indole-3-carboxamide;

(cc) FUB-144 IUPAC: [1-(4-fluorobenzyl)-1H-indol-3-yl](2,2,3,3-

tetramethylcyclopropyl)methanone (AKA FUB-UR-144);

(dd) MN-18 IUPAC: N-(1-Naphthyl)-1-pentyl-1H-indazole-3-carboxamide;

(ee) FUB-PB-22 IUPAC: Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-

carboxylate;

(ff) ADB-CHMINACA (N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-

(cyclohexylmethyl)-1H-indazole-3-carboxamide);

(gg) AMB-FUBINACA, (FUB-AMB), (methyl(1-(4-fluorobenzyl)-1H-indazole-3-

carbonyl)-L-valinate);

(hh) 5-fluoro-AMB (N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine,

methyl ester);

(ii) 5-fluoro-ADB (N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-

valine, methyl ester);

(jj) bk-DMBDB / dibutylone

(kk) MMB-FUBINACA, methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-

valinate

(ll) MDMB-CHMICA, methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-

carboxamido)-3,3-dimethylbutanoate

(mm) NM2201, Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate

(nn) Fluoro AKB48

(oo) Fluoro ADB

(pp) Fluoro AMB

(qq) MAB-CHMINACA

(r r ) SDB-006

(ss) Cumyl-PINACA/Cumyl-PICA

(tt) Unless specifically exempted or unless listed in another schedule, any material,

compound, mixture or preparation which contains any quantity of a substance which demonstrates

binding activity to the cannabinoid receptor or analogs or homologs with binding activity.

(36) Substances determined by the board to have the pharmacological effect of the substance,

the risk to the public health by abuse of the substance and the potential of the substance to produce psychic

or physiological dependence liability is similar to the substances described in Paragraph (1) or (2) of 30-31-23C

NMSA 1978. Substances include but are not limited to:

(a) salvia divinorum;

(b) salvinorin A (methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-

yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate);

(37) 4-methyl-ethylcathinone (4-MEC);

(38) 4-ethyl-methcathinone (4-EMC);

(39) 2-ethylamino-1-phenyl-propan-1-one (ethcathinone);

(40) 3’,4’-methylenedioxyethcathinone (ethylone);

(41) beta-keto-N-methyl-3,4-benzodioxyolybutanamine (bk-MBDB, butylone);

(42) naphthylpyrovalerone (NRG-1, naphyrone);

(43) N,N-dimethylcathinone (metamfepramone);

(44) alpha-pyrrolidinopropiophenone (alpha-PPP);

(45) alpha-pyrrolidinobutiophenone (α-PBP);

(46) 4’-methoxy-alpha-pyrrolidinopropiophenone (MOPPP);

(47) 4’-methyl-α-pyrrolidinopropiophenone (MPPP);

(48) 3’,4’-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP);

(49) 3’,4’-methylenedioxy-alpha-pyrrolidinobutiophenone (MDPBP);

(50) 4’-methyl-α-pyrrolidinobutiophenone (MPBP);

(51) alpha-pyrrolidinovalerophenone (alpha-PVP);

(52) 5,6-methylenedioxy-2-aminoindane (MDAI);

(53) alpha-methylamino-butyrophenone (buphedrone);

(54) beta-keto-ethylbenzodioxolylbutanamine (eutylone);

(55) beta-keto-ethylbenzodioxolylpentanamine;

(56) beta-keto-methylbenzodioxolylpentanamine (pentylone);

(57) 4-Bromo-2,5-dimethoxyphenethylamine (2c-B, Nexus);

(58) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alphamethyl-

3,4(methylenedioxy)-phenethylamine, and N-hydroxy MDA;

(59) 5-methoxy-N,N-dimethyltryptamine (5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-

MeO-DMT;

(60) 4-methylmethcathinone (Mephedrone);

(61) 3,4-methylenedioxypyrovalerone (MDPV);

(62) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);

(63) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);

(64) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);

(65) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T4);

(66) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);

(67) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);

(68) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);

(69) 3,4-Methylenedioxy-N-methylcathinone(Methylone);

(70) Aminorex (2-amino-5-phenyl-2-oxazoline);

(71) Pentedrone;

(72) 4-fluro-N-methylcathinone (4-FMC; flephedrone);

(73) 3-fluro-N-methylcathinone (3-FMC);

(74) 3-methylmethcathinone (3-MMC);

(75) 3,4-Dimethylmethcathinone (3,4 DMMC);

(76) 3-Methyl-N-ethylcathinone (3-MEC);

(77) 2-methylamino-1-(4-methylphenyl)butan-1-one (4-methylbuphedrone; 4-MeBP);

(78) 4-methylthioamphetamine (4 MTA);

(79) 5-methyl-3,4-methylenedioxyamphetamine (5-Me MDA);

(80) 6-benzofuran (6-APB);

(81) 4-methoxyamphetamine (PMA);

(82) 2,5-dimethoxy-4-bromophenethylamine (2C-B);

(83) 2,5-dimethoxy-4-chlorophenethylamine (2C-C);

(84) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);

(85) 2,5-dimethoxy-4-ethylphenethylamine, (2C-E, aquarust, cindy);

(86) 3,4-dimethyl-2,5-dimethoxyphenethylamine (2C-G);

(87) 2,5-dimethoxy-4-iodophenethylamine (2C-I);

(88) 2-[2,5-dimethoxy-4-(2-fluoroethylthio)phenyl]ethanamine (2C-T21);

(89) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine (2C-B-FLY);

(90) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine, (Bromo-DragonFLY, 3C-

Bromo-Dragonfly, DOB-Dragonfly);

(91) 2,5-Dimethoxy-4-bromoamphetamine (DOB);

(92) 2,5-Dimethoxy-4-chloroamphetamine (DOC);

(93) 2,5-Dimethoxy-4-methylamphetamine (DOM);

(94) 2,4,5-trimethoxyamphetamine (TMA2);

(95) 2,4,6-trimethoxyamphetamine (TMA6);

(96) 6,7-methylenedioxy-2-aminotetralin (MDAT);

(97) 4-acetoxy-N,N-diisopropyltryptamine (4-acetoxy DiPT, ipracetin);

(98) O-Acetylpsilocin (4-acetoxy DMT, psilacetin);

(99) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO MET, metocin);

(100) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO MiPT, hats);

(101) 5-methoxy-α-methyltryptamine, (5-MeO-aMT, Alpha-O);

(102) N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine (5-MeO-MiPT);

(103) N,N-diisopropyltryptamine (DiPT);

(104) dipropyltryptamine (DPT);

(105) N,N-diallyl-5-methoxytryptamine (5-MeO-DALT);

(106) 3-methoxyphencyclidine (3-MeO PCP);

(107) 4-methoxyphencyclidine (4-MeO PCP);

(108) dizocilpine (MK-801);

(109) tetrachloroethylene (PCE, perchloroethylene, perchloroethene, Perc);

(110) 3-MeO-2-Oxo-PCE (methoxetamine);

(111) phencyclamine, N-(1-phenylcyclohexyl)propanamine (PCPr);

(112) 1-(1-(2-thienyl)cyclohexyl)piperidine (Tenocyclidine);

(113) 3-methoxyeticyclidine, N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO PCE);

(114) 6-ethyl-6-nor-lysergic acid diethylamide (ETH-LAD);

(115) 6-allyl-6-nor-LSD (AL-LAD);

(116) 10-didehydroergoline-8-carboxamide (PRO-LAD);

(2)(117) 3, 4-methylenedioxymethamphetamine (MDMA), its optical, positional and geometric

isomers, salts and salts of isomers;

(5)(118) cathinone;

(6)(119) methcathinone.

(120) diethylone

F. Any material, compound, mixture ofor preparation which contains any quantity of the following

substances.

(1) 3-methylfentanyl(N-3-methyl-1-(2-phenyl-ethyl)-4-Piperidyl)-N-phenylpropanamide, its

optical and geometric isomers, salts and salts of isomers;

(2) 3, 4-methylenedioxymethamphetamine (MDMA), its optical, positional and geometric

isomers, salts and salts of isomers;

(3) 1-methyl-4-phenyl-4-proprionoxypiperidine (MPPP), its optical isomers, salts, and salts

of isomers;

(4)(1) 1-(-2-phenylethyl)-4-phenyl-4-acetoxy piperidine (PEPAP), its optical isomers, salts and

salts of isomers;

(5) cathinone;

(6) methcathinone.

(2) Tianeptene

[16.19.20.65 NMAC - Rp 16 NMAC 19.20.28, 07-15-02; A, 06-30-05; A, 01-15-08; A, 05-14-10; A, 11-27-11; A,

06-15-12; A, 08-31-12; A, 12-19-13; A, 06-28-14; A, 12-13-15; A, 10-19-16; A, 03-29-17]

16.19.20.66 SCHEDULE II:

B.A. OPIATES: NARCOTIC DRUGS: Unless specifically excepted or unless in another schedule

any of the following opiates narcotic drugs, including its isomers, esters, ethers, salts and salts of isomers, esters,

and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical

designation except dextrose dextro and levopropoxyphene.

(1) Alphaprodine

(2) Anileridine

(3) Bezitramide

(4) Diphenoxylate

(5) Dihydrocodeine

(6) Dextropropoxyphene (bulk) non-dosage form

(7) Fentanyl

(8) Isomethadone

(9) Levomethorphan

(10) Levorphanol

(11) Metazocine

(12) Methadone

(13) Methadone-Intermediate

(14) Monamide-Intermediate

(15) Pethidine

(16) Pethidine-Intermediate A

(17) Pethidine-Intermediate B

(18) Pethidine-Intermediate C

(19) Phenazocine

(20) Piminodine

(21) Racemethorphan

(22) Racemorphan

(23) Sufentanil

(24) Carfentanil

(25) Levo-alphacetylmethadol (LAAM)

(26) Tapentadol

A.B. Shall consist of the drugs and other substances, by whatever official name, common or usual name,

chemical name or brand name designated, listed in this section. Substance, vegetable origin or chemical synthesis.

Unless specifically exempt or unless listed in another schedule, any of the following substances whether produced

directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical

synthesis, or by a combination of extraction and chemical synthesis.

(1) Opium and opiate, and any salts, compound, derivative, or preparation of opium or opiate

excluding naloxone, dextrorphan, nalbuphine, naltrexone and apomorphine but including the following:

(a) raw opium

(b) opium extracts

(d) powdered opium

(e) granulated opium

(f) tincture of opium

(g) codeine

(h) ethylmorphine

(i) etorphine hydrochloride

(j) hydrocodone

(k) hydromorphone

(l) metopon

(m) morphine

(n) oxycodone

(o) oxymorphone

(p) thebaine

(q) alfentanil

(r) oripavine

(2) Any salt, compound derivative, or preparation thereof, which is chemically equivalent or

identical with any of the substances referred to in Paragraph (1) of Subsection A of 16.19.20.66 NMAC, except that

these substances shall not include the isoquinoline alkaloids of opium.

(3) Opium poppy and poppy straw.

(4) Coca leaves and any salt, compound, derivative or preparation of coca leaves and any

salt, compound, derivative or preparation thereof which is chemically equivalent or identical with any of these

substances, except that the substances shall not include de-cocainized coca leaves or extraction of coca leaves,

which extractions do not contain cocaine or ecgonine.

C. STIMULANTS: Unless specifically exempt or unless listed in another schedule, any material,

compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect

on the central nervous system. (See 16.19.21 NMAC- Drug Precursors)

(1) Amphetamine, its salts, optical isomers and salts of its optical isomers.

(2) Methamphetamine, its salts, isomers and salts of isomers.

(3) Phenmetrazine and its salts.

(4) Methylphenidate

(5) Lisdexamfetamine

D. DEPRESSANTS: Unless specifically exempt or unless listed in another schedule any material,

compound mixture or preparation which contains any quantity of the substance having a depressant effect on the

central nervous system, including its salts, isomers and salts of isomers is possible within the specific chemical

designation.

(1) Amobarbital

(2) Secobarbital

(3) Pentobarbital

(4) Phencyclidine

(5) Glutethimide

(6) 1-phenylcyclohexylamine

(7) 1-piperidinocyclohexanecarbonitrile

E. HALLUCINOGENIC SUBSTANCES: Unless specifically exempt or unless listed in another

schedule, any material, compound, mixture or preparation, which contains any quantity of the following

hallucinogenic substances, or which contains any of its salts, isomers and salts of isomers whenever the existence of

such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purpose of this

paragraph only, the term “isomers” includes the optical position, optical, positional and geometric isomers):

(1) Nabilone

(2) Phenylacetone (P2P, benzyl methyl ketone; methyl benzyl ketone)

F. MISCELLANEOUS:

(1) Dihydroetorphine

(2) Bulk dextropropoxyphene

(3) Remifentanil

[16.19.20.66 NMAC - Rp 16 NMAC 19.20.28(1), 07-15-02; A, 06-30-05; A, 01-15-08; A, 05-14-10; A, 06-28-14;

A, 12-13-15]

16.19.20.67 SCHEDULE III: Shall consist of drugs and other substances, by whatever official name,

common or usual name designated listed in this section.

E.A. NARCOTIC DRUGS: Unless specifically exempt or unless listed in another schedule, any

material, compound, mixture or preparation containing limited quantities of the following narcotic drugs, or any

salts thereof.

(1) Not more than one and eight-tenths grams of codeine per 100 milliliters or not more than

90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.

(2) Not more than one and eight-tenths grams of codeine per 100 milliliters or not more than

90 milligrams per dosage units, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.

(3) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than

15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.

(4) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than

15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(5) Not more than one and eight-tenths grams of dihydrocodeine per 100 milliliters or not

more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic

amounts.

(6) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15

milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(7) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more

than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic

amounts.

(8) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one

or more active, nonnarcotic ingredients in recognized therapeutic amounts.

A.B. STIMULANTS: Unless specifically exempt or unless listed in another schedule, any material,

compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect

on the central nervous system.

(1) Those compounds, mixtures or preparations in dosage unit form containing any

stimulant, amphetamine, phenmetrazine or methamphetamine previously exempt, for which the exemption was

revoked by FDA Regulation Title 21, Part 308.13, and any other drug of the quantitative composition shown in that

regulation for those drugs or which is the same except that it contains a lesser quantity of controlled substances.

(2) Benzphetamine.

(3) Phendimetrazine.

(4) Chlorphentermine.

(5) Clortermine.

B.C. DEPRESSANTS: Unless specifically exempt or unless listed in another schedule, any material,

compound, mixture or preparation which contains any quantity of the following substances having a depressant

effect on the central nervous system.

(1) Any compound, mixture or preparation containing:

(a) amobarbital;

(b) secobarbital;

(d) butalbital; or any salt thereof and one or more active medicinal ingredients

which are not listed in any schedule.

(2) Any suppository dosage form containing:

(a) amobarbital;

(b) secobarbital;

marketing only as a suppository.

(3) Any substance which contains any quantity of a derivative of barbituric acid or any salt

of a derivative of barbituric acid.

(4) Chlorhexadol

(5) Lysergic Acid

(6) Lysergic Acid Amide

(7) Methyprylon

(8) Sulfondiethylmethane

(9) Sulfonethylmethane

(10) Sulfonmethane

(11) Tiletamine/zolazepam (Telazol)

(12) Ketamine Hydrochloride

(13) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers,

and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug and Cosmetic

Act.

(14) Embutramide

(15) Dronabinol (synthetic) in sesame oil and encapsulated in soft gelatin capsules in a drug

product approved by the U.S. food and drug administration.

(16) Perampanel

C. Nalorphine (a narcotic drug).

D. Buprenorphine.

D. MISCELLANEOUS

(1) Nalorphine

(2) Buprenorphine

(3) Clenbuterol

F.E. ANABOLIC STEROIDS: The term “anabolic steroid” means any drug or hormonal substance,

chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) that

promotes muscle growth. Unless specifically exempt or unless listed in another schedule, any material, compound,

mixture or preparation which contains any quantity of the following substances listed in this section:

(1) boldenone

(2) chloro testosterone

(3) clostebol

(4) dehydrochlormethyltestosterone

(5) dihydrotestosterone

(6) drostanolone

(7) ethylestrenol

(8) fluoxymesterone

(9) formebolone

(10) mestanolone

(11) mesterolone

(12) methandienone

(13) methandranone

(14) methandriol

(15) methandrostenolone

(16) methenolone

(17) methyltrienolone

(18) methyltestosterone

(19) mibolerone

(20) nandrolone

(21) norbolethone

(22) norethandrolone

(23) oxandrolone

(24) oxymesterone

(25) oxymetholone

(26) stanolone

(27) stanozolol

(28) testolactone

(29) testosterone

(30) trenbolone; and

(31) any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if

that salt, ester, or isomer promotes muscle growth.

G.F. Exempt anabolic steroids: Compounds, mixtures, or preparations that contain an anabolic steroid

that have been exempted by the board from Subsection E of 16.19.20.67 NMAC, Schedule III to the same extent

that the substance has been exempted from the application of the Federal Controlled Substance Act, if the substance

is listed as an exempt anabolic steroid product under 21 C.F.R. Section 1308.34 and its subsequent amendments.

[16.19.20.67 NMAC - Rp 16 NMAC 19.20.28(2), 07-15-02; A, 02-15-03; A, 06-30-05; A, 01-31-07; A, 01-15-08;

A, 05-14-10; A, 06-28-14]

16.19.20.68 SCHEDULE IV: Shall consist of the drugs and other substances, by whatever official name,

common or usual name, chemical name, or brand name designated, listed in this section:

F.A. NARCOTIC DRUG: Unless specifically exempt or unless listed in another schedule, any

material, compound, mixture or preparation containing limited quantities of any of the following narcotic drugs or

any salts thereof: Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per

dosage unit.

D.B. STIMULANTS: Unless specifically exempt or unless listed in another schedule any material,

compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect

on the central nervous system, including its salts, isomers (whether optical position optical, positional or geometric)

and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible within the

specific chemical designation:

(1) Diethylpropion

(2) Phentermine

(3) Pemoline (including organometallic complexes and chelates thereon)

(4) Pipradrol

(5) SPA ((-)-1-dimethyl amino-1,2-diphenylmethane)

(6) Mazindol

(7) Cathine

(8) Fencamfamin

(9) Fenproporex

(10) Mefenorex

(11) Modafinil

(12) Sibutramine

A.C. DEPRESSANTS: Unless specifically exempt or unless listed in another schedule, any material,

compound, mixture or preparation which contains any quantity of the following substances, including its salts,

isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the

specific chemical designation:

(1) Alfaxalone

(2) Alprazolam

(3) Barbital

(4) Chloral Betaine

(5) Chloral Hydrate

(6) Chlordiazepoxide

(7) Clobazam

(8) Clonazepam

(9) Clorazepate

(10) Clotiazepam

(11) Diazepam

(12) Estazolam

(13) Ethchlorvynol

(14) Ethinamate

(15) Flurazepam

(16) Fospropofol

(17) Halazepam

(18) Lorazepam

(19) Mebutamate

(20) Meprobamate

(21) Methohexital

(22) Methylphenobarbital

(23) Midazolam

(24) Oxazepam

(25) Paraldehyde

(26) Petrichloral

(27) Phenobarbital

(28) Prazepam

(29) Quazepam

(30) Suvorexant

(31) Temazepam

(32) Triazolam

(33) Zopiclone

B.D. FENFLURAMINE: Any material, compound, mixture or preparation which contains any

quantity of the following substance, including its salts, isomers (whether optical position optical, positional or

geometric) and its salts, or such isomers, whenever the existence of such salts, isomers, and salts of isomers is

possible: Fenfluramine

C.E. LORCASERIN: Any material, compound, mixture or preparation which contains any quantity of

the following substance, including its salts, isomers (whether optical position, optical, positional or geometric) and

its salts, or such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible: Lorcaserin

E.F. OTHER SUBSTANCES: Unless specifically exempt or unless listed in another schedule, any

material, compound, mixture or preparation which contains any quantity of the following substances, including its

salts:

(1) Dextropropoxyphene(Alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-

propionoxybutane)

(2) Pentazocine

(3) Carisoprodol

(4) Nalbuphine Hydrochloride

(5) Butorphanol Tartrate

(6) Dezocine

(7) Dichloralphenazone

(8) Zaleplon

(9) Zolpidem

(10) Tramadol

(11) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-

oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical

isomers) and its salts, isomers, and salts of isomers.

G. EXEMPTION OF CHLORAL: When packaged in a sealed, oxygen-free environment, under nitrogen

pressure, safeguarded against exposure to the air. Chloral when existing under the above conditions is a substance

which is not intended for general administration to a human being or another animal, and contains no narcotic

controlled substances and is packaged in such a form that the package quantity does not present any significant

potential for abuse. All persons who engage in industrial activities with respect to such chloral are subject to

registration; but shall be exempt from Section 30-31-16 through 19 of the New Mexico Controlled Substances Act

and 16.19.20.19 NMAC through 16.19.20.52 NMAC of the board of pharmacy regulations.

H. EXEMPT COMPOUNDS: Librax and Menrium are preparations which contain

chlordiazepoxide, a depressant listed in Schedule IV, 16.19.20.68.A.5 NMAC and other ingredients in such

combinations, quantity, preparation or concentration as to vitiate the potential for abuse of chlordiazepoxide, and are

hereby exempt preparations.

(1) Librax

(2) Menrium, 5-2

(3) Menrium, 4-5

(4) Menrium, 10-4

[16.19.20.68 NMAC - Rp 16 NMAC 19.20.28(3), 07-15-02; A, 06-30-05; A, 05-14-10; A, 03-07-11; A, 08-31-12;

A, 09-07-14; A, 12-13-15; A, 03-29-17]